Shopping Cart 0
Cart Subtotal
USD 0

GW Pharmaceuticals Plc (GWPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company's commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the treatment of spasticity due to multiple sclerosis. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. GW Pharmaceuticals is also developing products for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis, infantile spasms, epilepsy syndrome, glioma, schizophrenia, autism among others. The company has subsidiaries in Australia, the US, England and Wales, and Guernsey. GW Pharmaceuticals is headquartered in Cambridgeshire, the UK.

GW Pharmaceuticals Plc (GWPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GW Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 10

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 12

Private Equity 12

Mentor Capital Invests USD1 Million in GW Pharma 12

Partnerships 13

GW Pharma Enters into Research Agreement with New South Wales 13

GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 14

Equity Offering 15

GW Pharma Raises USD345.2 Million in Public Offering of American Depositary Shares 15

GW Pharma Raises USD317.4 Million in Public Offering of Shares 17

GW Pharma Raises USD290 Million in Public Offering of American Depositary Shares 19

GW Pharma Completes Exercise of Underwriter's Over Allotment Option for Public Offering of ADSs for USD206 Million 21

GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 23

GW Pharma Completes Public Offering Of American Depositary Shares For USD 101 Million 25

GW Pharma Announces Partial Exercise Of Underwriter's Option Of American Depository Shares For USD 33 Million 27

Acquisition 29

GW Pharma May Sell Itself 29

GW Pharmaceuticals Plc-Key Competitors 30

GW Pharmaceuticals Plc-Key Employees 31

GW Pharmaceuticals Plc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Aug 07, 2018: GW Pharmaceuticals reports fiscal third quarter 2018 financial results and operational progress 33

May 08, 2018: GW Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results 35

Feb 05, 2018: GW Pharmaceuticals Reports Q1 Fiscal 2018 Financial Results 36

Dec 04, 2017: GW Pharmaceuticals Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress 38

Aug 07, 2017: GW Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results 40

May 09, 2017: GW Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress 42

Feb 07, 2017: GW Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Progress 44

Corporate Communications 45

Dec 21, 2017: GW Pharmaceuticals Announces the Appointment of Three New Independent Members to its Board of Directors 45

May 15, 2017: GW Pharmaceuticals Announces Research & Development Management Appointments 46

Mar 07, 2017: GW Pharmaceuticals Announces the Appointment of Scott Giacobello as Chief Financial Officer and Adam George as Managing Director-UK 47

Legal and Regulatory 48

Aug 02, 2018: Certara Software or Services supported 95% of the US FDA novel drug approvals in first half of 2018 48

Government and Public Interest 49

Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GW Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GW Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 9

GW Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 10

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Mentor Capital Invests USD1 Million in GW Pharma 12

GW Pharma Enters into Research Agreement with New South Wales 13

GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 14

GW Pharma Raises USD345.2 Million in Public Offering of American Depositary Shares 15

GW Pharma Raises USD317.4 Million in Public Offering of Shares 17

GW Pharma Raises USD290 Million in Public Offering of American Depositary Shares 19

GW Pharma Completes Exercise of Underwriter's Over Allotment Option for Public Offering of ADSs for USD206 Million 21

GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 23

GW Pharma Completes Public Offering Of American Depositary Shares For USD 101 Million 25

GW Pharma Announces Partial Exercise Of Underwriter's Option Of American Depository Shares For USD 33 Million 27

GW Pharma May Sell Itself 29

GW Pharmaceuticals Plc, Key Competitors 30

GW Pharmaceuticals Plc, Key Employees 31

GW Pharmaceuticals Plc, Other Locations 32

GW Pharmaceuticals Plc, Subsidiaries 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

GW Pharmaceuticals Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company's commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the treatment of spasticity due to multiple sclerosis. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. GW Pharmaceuticals is also developing products for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis, infantile spasms, epilepsy syndrome, glioma, schizophrenia, autism among others. The company has subsidiaries in Australia, the US, England and Wales, and Guernsey. GW Pharmaceuticals is headquartered in Cambridgeshire, the UK.

GW Pharmaceuticals Plc (GWPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GW Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 10

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 12

Private Equity 12

Mentor Capital Invests USD1 Million in GW Pharma 12

Partnerships 13

GW Pharma Enters into Research Agreement with New South Wales 13

GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 14

Equity Offering 15

GW Pharma Raises USD345.2 Million in Public Offering of American Depositary Shares 15

GW Pharma Raises USD317.4 Million in Public Offering of Shares 17

GW Pharma Raises USD290 Million in Public Offering of American Depositary Shares 19

GW Pharma Completes Exercise of Underwriter's Over Allotment Option for Public Offering of ADSs for USD206 Million 21

GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 23

GW Pharma Completes Public Offering Of American Depositary Shares For USD 101 Million 25

GW Pharma Announces Partial Exercise Of Underwriter's Option Of American Depository Shares For USD 33 Million 27

Acquisition 29

GW Pharma May Sell Itself 29

GW Pharmaceuticals Plc-Key Competitors 30

GW Pharmaceuticals Plc-Key Employees 31

GW Pharmaceuticals Plc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Aug 07, 2018: GW Pharmaceuticals reports fiscal third quarter 2018 financial results and operational progress 33

May 08, 2018: GW Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results 35

Feb 05, 2018: GW Pharmaceuticals Reports Q1 Fiscal 2018 Financial Results 36

Dec 04, 2017: GW Pharmaceuticals Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress 38

Aug 07, 2017: GW Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results 40

May 09, 2017: GW Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress 42

Feb 07, 2017: GW Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Progress 44

Corporate Communications 45

Dec 21, 2017: GW Pharmaceuticals Announces the Appointment of Three New Independent Members to its Board of Directors 45

May 15, 2017: GW Pharmaceuticals Announces Research & Development Management Appointments 46

Mar 07, 2017: GW Pharmaceuticals Announces the Appointment of Scott Giacobello as Chief Financial Officer and Adam George as Managing Director-UK 47

Legal and Regulatory 48

Aug 02, 2018: Certara Software or Services supported 95% of the US FDA novel drug approvals in first half of 2018 48

Government and Public Interest 49

Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GW Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GW Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 9

GW Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 10

GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Mentor Capital Invests USD1 Million in GW Pharma 12

GW Pharma Enters into Research Agreement with New South Wales 13

GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 14

GW Pharma Raises USD345.2 Million in Public Offering of American Depositary Shares 15

GW Pharma Raises USD317.4 Million in Public Offering of Shares 17

GW Pharma Raises USD290 Million in Public Offering of American Depositary Shares 19

GW Pharma Completes Exercise of Underwriter's Over Allotment Option for Public Offering of ADSs for USD206 Million 21

GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 23

GW Pharma Completes Public Offering Of American Depositary Shares For USD 101 Million 25

GW Pharma Announces Partial Exercise Of Underwriter's Option Of American Depository Shares For USD 33 Million 27

GW Pharma May Sell Itself 29

GW Pharmaceuticals Plc, Key Competitors 30

GW Pharmaceuticals Plc, Key Employees 31

GW Pharmaceuticals Plc, Other Locations 32

GW Pharmaceuticals Plc, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

GW Pharmaceuticals Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.